Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 6/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | PDE9A | O76083 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17914538 | 0.88 | PDE2A (0.44) | OPRL1PDE2ACHRNB2CHRNA4 | |
| SCHEMBL15577422 | 0.87 | RPS6KA3 (0.38) | OPRL1MAOARPS6KA3PDE2ACHRNB2 | |
| SCHEMBL24664746 | 0.85 | PDE2A (0.40) | OPRL1PDE2ACHRNB2CHRNA4 | |
| SCHEMBL13499048 | 0.85 | APP (0.41) | OPRL1PDE2ACHRNB2CHRNA4 | |
| SCHEMBL25693956 | 0.83 | CHRNB2 (0.37) | PDE2ACHRNB2CHRNA4GAA | |
| SCHEMBL16285922 | 0.83 | APP (0.43) | OPRL1PDE2ACHRNB2CHRNA4 | |
| SCHEMBL22502744 | 0.82 | PDE2A (0.41) | OPRL1PDE2ACHRNB2CHRNA4 | |
| SCHEMBL15785387 | 0.81 | HTR6 (0.45) | PDE2ACHRNB2CHRNA4TLR9TLR8 | |
| SCHEMBL19245044 | 0.81 | CHRNB2 (0.35) | OPRL1CHRNB2CHRNA4KIF11GAA | |
| SCHEMBL11977022 | 0.79 | TLR9 (0.44) | OPRL1PDE2ACHRNB2CHRNA4TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200354408-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-11-12 | — | — | US | disclosed |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190307838-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-10-10 | — | — | US | disclosed |
| US-20190248840-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-08-15 | — | — | US | disclosed |
| US-10344056-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170022253-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344056-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | OPRL1 2279/4885MAOA 3170/4885RPS6KA3 3521/4885 |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | OPRL1 2349/4885MAOA 2761/4885RPS6KA3 2648/4885 |
| US-20170022253-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | OPRL1 2560/4885MAOA 3007/4885RPS6KA3 3432/4885 |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | ENPP2, ROCK2, RRP12 | OPRL1 1493/4885MAOA 2904/4885RPS6KA3 1018/4885 |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | OPRL1 2279/4885MAOA 3170/4885RPS6KA3 3521/4885 |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | OPRL1 2560/4885MAOA 3007/4885RPS6KA3 3432/4885 |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | OPRL1 2279/4885MAOA 3170/4885RPS6KA3 3521/4885 |
| US-20190248840-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | OPRL1 2279/4885MAOA 3170/4885RPS6KA3 3521/4885 |
| US-20190307838-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | ENPP2, ROCK2, RRP12 | OPRL1 1493/4885MAOA 2904/4885RPS6KA3 1018/4885 |
| US-20200354408-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | OPRL1 2560/4885MAOA 3007/4885RPS6KA3 3432/4885 |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | OPRL1 2279/4885MAOA 3170/4885RPS6KA3 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.